SCHEMBL5357858

SCHEMBL5357858

CNS(=O)(=O)c1ccc2c(c1)C(=Cc1cc(C)c(OC)c(C)c1)C(=O)N2

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 2/20 0.65
NTRK1 P04629 1/20 0.55
FCER2 P06734 1/20 0.55
SYK P43405 1/20 0.55
NTRK3 Q16288 1/20 0.55
NTRK2 Q16620 1/20 0.55
SRC P12931 8/20 0.53
CDK2 P24941 2/20 0.52
KDR P35968 6/20 0.50
LCK P06239 5/20 0.49
FYN P06241 5/20 0.49
YES1 P07947 5/20 0.49
PDGFRB P09619 5/20 0.49
FGFR1 P11362 5/20 0.49
GSK3B P49841 2/20 0.48
PLK4 O00444 1/20 0.48
AURKA O14965 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5367766 0.89 GSK3B (0.61) LRRK2NTRK1FCER2SYKNTRK3
SCHEMBL7138911 0.87 NTRK1 (0.54) LRRK2NTRK1FCER2SYKNTRK3
SCHEMBL5361428 0.87 LRRK2 (0.64) LRRK2NTRK1FCER2SYKNTRK3
SCHEMBL5363360 0.87 SYK (0.62) LRRK2NTRK1FCER2SYKNTRK3
SCHEMBL5368923 0.86 ERBB2 (0.59) LRRK2NTRK1FCER2SYKNTRK3
SCHEMBL5373774 0.86 SYK (0.53) LRRK2NTRK1FCER2SYKNTRK3
SCHEMBL5368362 0.85 SRC (0.49) LRRK2NTRK1FCER2SYKNTRK3
SCHEMBL5361448 0.84 SYK (0.65) LRRK2NTRK1FCER2SYKNTRK3
SCHEMBL7138006 0.84 SRC (0.57) LRRK2NTRK1FCER2SYKNTRK3
SCHEMBL7136883 0.83 SRC (0.58) NTRK1FCER2SYKNTRK3NTRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK LRRK2 289/4885NTRK1 223/4885FCER2 1878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.